Product Description
Product Name: Combinib Tablets
Active Ingredient: Lapatinib
Strength: 250 mg
Form: Oral Tablet
Category: Anticancer / Tyrosine Kinase Inhibitor
Indication: HER2-Positive Breast Cancer
Combinib (Lapatinib 250 mg Tablets) is an oral targeted therapy used in the treatment of HER2-positive breast cancer, particularly in patients who have not responded to other therapies. Lapatinib is a dual tyrosine kinase inhibitor that blocks both HER2 and EGFR receptors, helping to inhibit the growth of cancer cells.
